

Chi-Chung Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6984238/publications.pdf>

Version: 2024-02-01

26
papers

1,380
citations

471061

17
h-index

552369

26
g-index

26
all docs

26
docs citations

26
times ranked

1201
citing authors

#	ARTICLE	IF	CITATIONS
1	Modeling Ophthalmic Drug Delivery by Soaked Contact Lenses. <i>Industrial & Engineering Chemistry Research</i> , 2006, 45, 3718-3734.	1.8	201
2	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	0.8	160
3	Dispersion of DMPC Liposomes in Contact Lenses for Ophthalmic Drug Delivery. <i>Current Eye Research</i> , 2005, 30, 1071-1080.	0.7	139
4	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2022, 23, 1055-1065.	5.1	119
5	In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [¹¹ C]MK-4232. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 347, 478-486.	1.3	114
6	Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 15-22.	1.1	79
7	Timolol transport from microemulsions trapped in HEMA gels. <i>Journal of Colloid and Interface Science</i> , 2007, 315, 297-306.	5.0	77
8	Pharmacological Properties of MK-3207, a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 333, 152-160.	1.3	71
9	Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. <i>Npj Systems Biology and Applications</i> , 2020, 6, 28.	1.4	61
10	Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist. <i>ACS Medicinal Chemistry Letters</i> , 2010, 1, 24-29.	1.3	55
11	A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 459-476.	1.1	48
12	Characterization of Ubrogapant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor*. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, , jpet.119.261065.	1.3	36
13	Population PK Analyses of Ubrogapant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 294-303.	1.0	34
14	Population Pharmacokinetics and Pharmacodynamics of Caspofungin in Pediatric Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2098-2105.	1.4	31
15	Effect of Different Durations and Formulations of Diltiazem on the Single-Dose Pharmacokinetics of Midazolam: How Long Do We Go?. <i>Journal of Clinical Pharmacology</i> , 2011, 51, 1561-1570.	1.0	29
16	A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 486-495.	2.3	23
17	Characterizing the PK/PD relationship for inhibition of capsaicin-induced dermal vasodilatation by MK-3207, an oral calcitonin gene related peptide receptor antagonist. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 831-837.	1.1	20
18	Ubrogapant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males. <i>Clinical and Translational Science</i> , 2020, 13, 462-472.	1.5	15

#	ARTICLE	IF	CITATIONS
19	Industrial Perspective on the Benefits Realized From the FDA's Model-Informed Drug Development Paired Meeting Pilot Program. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1172-1175.	2.3	15
20	Pharmacokinetics and Tolerability of Rizatriptan in Pediatric Migraineurs in a Randomized Study. <i>Headache</i> , 2012, 52, 625-635.	1.8	14
21	Quantitative Clinical Pharmacology of Cell Engaging Bispecifics: Current Perspectives and Opportunities. <i>Clinical and Translational Science</i> , 2021, 14, 75-85.	1.5	12
22	Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1285-1285.	0.6	9
23	Tumor Time-Course Predicts Overall Survival in Non-Small Cell Lung Cancer Patients Treated with Atezolizumab: Dependency on Follow-Up Time. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 115-123.	1.3	8
24	The effect of multiple doses of ubrogepant on the pharmacokinetics of an oral contraceptive in healthy women: Results of an open-label, single-center, two-period, fixed-sequence study. <i>Cephalalgia Reports</i> , 2020, 3, 251581632090508.	0.2	5
25	Making Better Dose Decisions: Using Exposure-Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment. <i>Clinical and Translational Science</i> , 2020, 13, 482-490.	1.5	3
26	The role of clinical pharmacology across novel treatment modalities. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 413-415.	2.3	2